Dr. Christopher Gibbons and his team at CND Life Sciences are conducting a new research study to identify Essential Tremor (ET) patients who may be at risk of developing Parkinson’s disease. If you are between 50-85 years old and have been diagnosed with essential tremor or essential tremor-plus, you may be eligible to participate.
This two-year observational study involves skin biopsies to detect phosphorylated α-synuclein, a biomarker that may indicate early Parkinson’s disease. Participants will undergo comprehensive neurological assessments and follow-up evaluations. Compensation of $250 per completed visit is provided.
The study is being conducted at select movement disorder and clinical research centers across the United States. Enrollment is available through participating sites only — patients must be seen at a study site to be eligible.
To find out if there is a participating site near you, please visit ClinicalTrials.gov and search for “Syn-T” or “essential tremor alpha-synuclein.” You may also email the study team at ClinicalResearch@CNDLifeSciences.com with your name, telephone number, age, and diagnosis information, and they will help connect you with a site in your area, if there is one close by.